Navigation Links
Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia
Date:2/17/2013

ZURICH, February 18, 2013 /PRNewswire/ --

Neurim Pharmaceuticals announced today positive results from a phase II clinical study evaluating the efficacy and safety of Piromelatine (Neu-P11), a novel investigational multimodal sleep medicine developed for the treatment of patients with primary and co-morbid insomnia. The new results are from a  recent double-blind, randomized, placebo controlled, parallel group, non-confirmatory, sleep-laboratory study. The study evaluated piromelatine compared to placebo in 120 adult primary insomnia patients ages 18 years and older.

Piromelatine 20/50mg treatment for 4 weeks resulted in statistically significant and clinically meaningful improvements relative to placebo in key  polysomnographic (PSG) parameters including Wake After Sleep Onset (WASO) (p=0.02 for both doses) and in particular WASO for the first 6 hours of sleep (WASO-6h) (p=0.0008 and p=0.04 for the 50 mg and 20 mg groups, respectively). Piromelatine 50 mg also improved Sleep Efficiency (SEF) (p=0.02), Total Sleep Time (TST) (p=0.02), Total Time Awake (TTA) (p=0.01) and time in NREM sleep (p=0.028) indicating beneficial effects on sleep maintenance. Subjective improvements relative to placebo in quality of sleep and total sleep time measured by the Pittsburg Sleep Quality Questionnaire (PSQI) were also observed, confirming the PSG findings. Piromelatine enhanced NREM sleep EEG delta power and significantly reduced beta power (p<0.05). The decrease in EEG beta activity, a marker of cortical arousal, is a physiological surrogate marker of the efficacy of Piromelatine in sleep maintenance. Piromelatine was generally safe and well tolerated, had no detrimental effects on next-day psychomotor performance (as assessed by the Digit Symbol Substitution Test (DSST)) for any dose group and no deleterious effects on sleep structure and architecture.

"Piromelatine demonstrates a good potential for the treatm
'/>"/>

SOURCE Neurim Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015 Research and Markets ( ... the "Wound Care -Traditonal, Advanced And ... And Forecasts" report to their offering. ... of the global Wound Care products market, ... offerings, competitive shares, financial performance, technology developments ...
(Date:7/27/2015)... 2015 According to the new ... (2014-2019) by Type (DNA ISH, RNA ISH), By Application ... (Hospitals, Pharma & Biotech Companies, Research Labs, CROs)", The ... 2014 and is estimated to reach $681.0 million by ... period, 2014 to 2019. Browse through the ...
(Date:7/27/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/v4wlnk/key_pharma_news ) has ... News Issue" newsletter to their offering. ... oncology pipeline and serves as a statement of ... 2015, with a large-scale potentially transformative acquisition by ... Pharma News covers all major developments in the ...
Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 2Global In-Situ Hybridization Market to be Worth $681.0 Million by 2019 3Key Pharma News Issue - Gilead will make further oncology deals in 2015 2Key Pharma News Issue - Gilead will make further oncology deals in 2015 3
... Colo., Oct. 14, 2011 Data presented at ... in Chicago, IL show that the pretreatment blood-based ... carcinoma (RCC) patients treated with a combination of ... by survival outcomes.   Patients who tested VeriStrat ...
... Pharmaceuticals, Inc. announced Friday a significant expansion of its ... methyl, and to continue advancing its earlier-stage pipeline. ... Paul Audhya, MD, as Vice President of ... Ph.D., as Vice President and Chief Regulatory and Compliance ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:7/28/2015)... , ... July 28, 2015 , ... Want to improve ... – or in your easy chair? Luckily, there are plenty of back-friendly cardio exercises ... an orthopedic spine surgeon at Atlantic Spine Center . , It’s simply ...
(Date:7/27/2015)... , ... July 28, 2015 , ... Almost a year ... to offer behavioral health counseling for persons who are obese and those who are ... less clear. , That mandate will affect any commercial health plan with a program ...
(Date:7/27/2015)... (PRWEB) , ... July 28, 2015 , ... The ... 2015-2016 inductee into the NAPW VIP Woman of the Year Circle. She is recognized ... over 200 operating Local Chapters, NAPW is the nation’s leading networking organization exclusively for ...
(Date:7/27/2015)... , ... July 27, 2015 , ... The heroin epidemic ... reported WCNC on July 7th. The rate for heroin usage has continued ... gone down considerably, and is a less expensive alternative for those with an addiction ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... Looking to ... smile? Horizon Blue Cross Blue Shield of New Jersey has enhanced its Dental webpage ... take care of their teeth. , “Horizon is committed to offering our 3.8 ...
Breaking Medicine News(10 mins):Health News:Safe Cardio for Back Pain Sufferers 2Health News:Safe Cardio for Back Pain Sufferers 3Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:NAPW Inducts Deana Skidmore, Assistant Director of Nursing at Wilton Meadows Rehablilitation and Health Care Center, Into its VIP Woman of the Year Circle 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 2Health News:45% Of People Addicted to Heroin Began Addicted to Prescription Medications 3Health News:Thinking about a Dental Check-up? Check out Horizon Blue Cross Blue Shield of New Jersey’s Enhanced Website for a Dental Download of Helpful Information 2
... reimburses patients and physicians who have been shortchanged ... American Medical Association (AMA), along with the Medical Society ... State Medical Association, claims victory with the settlement agreement ... The $350 million settlement marks the largest monetary settlement ...
... Philadelphia Attorney Stephen Sheller,s Whistleblower Clients Help ... Criminal Fine in Eli Lilly & Company ... 2003 Representing Six Whistleblowers PHILADELPHIA, Jan. 15 ... ("Lilly") will pay federal and state governments ...
... Eli Lilly and Company announced today it has ... pay more than 1.4 billion in criminal and civil ... multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, ... with its market practices for its blockbuster atypical antipsychotic, ...
... transplanted because of the generosity of donors and their familiesPHILADELPHIA, ... kid on the football field, but he spent his life ... graduated high school. For a 16-year-old from Hazleton, Pa. ... certainly unique. But as his father Paul Sr. talked ...
... $515 Million Criminal Fine is Largest Individual Corporate Criminal ... 15 American pharmaceutical giant Eli Lilly and Company ... for promoting its drug Zyprexa for uses not approved ... of Justice announced today. This resolution includes ...
... CINCINNATI, Jan. 15, 2009 The Procter & Gamble,Company ... organizational changes: , -- Mariano ... June 30, 2009, after 33 years of service. He ... 2009, when he will focus on working,closely with his ...
Cached Medicine News:Health News:AMA Claims Victory With Record Breaking Settlement in Case Against Insurer 2Health News:The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion 2Health News:The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion 3Health News:The Largest Pharma Fraud Whistleblower Case in U.S. History Totaling $1.4 Billion 4Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 2Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 3Health News:Eli Lilly Pays a Record $1.4 Billion to Settle Federal and State Fraud Investigations into Illegal Zyprexa Off-Label Marketing Practices 4Health News:Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation 2Health News:Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation 3Health News:Gift of Life Celebrates 35th Anniversary as National Leader in Organ Donation 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 2Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 3Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 4Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 5Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 6Health News:Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-Label Promotion of Zyprexa 7Health News:Procter & Gamble Announces Organizational Changes 2